Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.
- Send an email
- Get directions
- Bookmark
- Share
- Report
- prev
- next
Location
-
Bleicherweg 10, 8002 Zürich, Switzerland
Canton
Facts & figures
-
Type of organizationPrivate company
-
Year of foundation2023
-
Number of employees in Switzerland1-9
Core competencies
You may also be interested in
FoRx Therapeutics AG 
- R&D
Member
Solvias AG
- R&D, Service provider, Supplier
Member
EraCal Therapeutics Ltd
- R&D
Member